Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) received a $30 million development milestone payment on Oct 24, 2025 after dosing the first patient in the frontline acute myeloid leukemia (AML) Phase 3 program for ziftomenib under its collaboration with Kyowa Kirin.
The payment followed the Sept 29, 2025 launch of KOMET-017 (NCT07007312), two global, randomized, double-blind, placebo-controlled Phase 3 trials testing once-daily oral menin inhibitor ziftomenib in newly diagnosed NPM1-mutated or KMT2A-rearranged AML across both intensive and non-intensive chemotherapy regimens.
Kura states KOMET-017 is the only menin inhibitor registrational program pursuing both chemotherapy settings.
Positive
- $30 million milestone payment received on Oct 24, 2025
- KOMET-017 launched on Sept 29, 2025
- Phase 3 registrational trials initiated (KOMET-017, NCT07007312)
- Program targets both intensive and non-intensive chemotherapy settings
Negative
- None.
News Market Reaction
On the day this news was published, KURA gained 6.59%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.2% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $49M to the company's valuation, bringing the market cap to $790M at that time.
Data tracked by StockTitan Argus on the day of publication.
- Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program-
SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a
KOMET-017 (NCT07007312) comprises two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Kura believes KOMET-017 is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the therapeutic potential of ziftomenib and the KOMET-017 trial being the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, the risk that the collaboration with Kyowa Kirin is unsuccessful, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
Why did Kura Oncology (KURA) receive a $30 million payment on Oct 24, 2025?
What is KOMET-017 (NCT07007312) launched Sept 29, 2025 for KURA?
How does KOMET-017 evaluate ziftomenib across chemotherapy settings for KURA stockholders?
What drug is KURA developing with Kyowa Kirin in the Oct 24, 2025 announcement?
Does the Oct 24, 2025 milestone signal a change in trial status for KURA?
